BindingDB logo
myBDB logout

13 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
18630896 10 Structure-based development of novel adenylyl cyclase inhibitors.EBI Ruhr-University Bochum
15743197 37 Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.EBI Universit£ di Camerino
8691441 19 Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.EBI University of Arizona
1548682 74 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.EBI Kyowa Hakko Kogyo Co., Ltd.
1973733 17 Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.EBI Royal Danish School of Pharmacy
12747789 29 Metal coordination-based inhibitors of adenylyl cyclase: novel potent P-site antagonists.EBI Millennium Pharmaceuticals, Inc.
12372508 20 Hydroxamate based inhibitors of adenylyl cyclase. Part 2: the effect of cyclic linkers on P-site binding.EBI Millennium Pharmaceuticals, Inc.
12372507 30 Hydroxamate based inhibitors of adenylyl cyclase. Part 1: the effect of acyclic linkers on P-site binding.EBI Millennium Pharmaceuticals, Inc.
10937732 15 6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists.EBI NPS Allelix Corp.
8709105 134 Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.EBI Food and Drug Administration
8887981 72 A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.BDB Abbott Laboratories
7518514 46 (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.BDB Abbott Laboratories
1397049 24 NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.BDB Novo Nordisk